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The genetic analysis of early-onset Parkinsonian disorder (EOPD) is part of the clinical 
diagnostics. Several genes have been implicated in the genetic background of 
Parkinsonism, which is clinically indistinguishable from idiopathic Parkinson's disease. 
The identification of patient's genotype could support clinical decision-making process 
and also track and analyse outcomes in a comprehensive fashion. The aim of our study 
was to analyse the genetic background of EOPD in a Hungarian cohort and to evaluate the 
clinical usefulness of different genetic investigations. The age of onset was between 25 and 
50 years. To identify genetic alterations, multiplex ligation-dependent probe amplification 
(n = 142), Sanger sequencing of the most common PD-associated genes (n = 142), and 
next-generation sequencing (n = 54) of 127 genes which were previously associated 
to neurodegenerative disorders were carried out. The genetic analysis identified several 
heterozygous damaging substitutions in PD-associated genes (C19orf12, DNAJC6, 
DNAJC13, EIF4G1, LRRK2, PRKN, PINK1, PLA2G6, SYNJ1). CNVs in PRKN and SNCA 
genes were found in five patients. In our cohort, nine previously published genetic risk 
factors were detected in three genes (GBA, LRRK2, and PINK1). In nine cases, two or 
three coexisting pathogenic mutations and risk variants were identified. Advances of 
sequencing technologies make it possible to aid diagnostics of PD by widening the scope 
of analysis to genes which were previously linked to other neurodegenerative disorders. 
Our data suggested that rare damaging variants are enriched versus neutral variants, 
among PD patients in the Hungarian population, which raise the possibility of an oligogenic 
effect. Heterozygous mutations of multiple recessive genes involved in the same pathway 
may perturb the molecular process linked to PD pathogenesis. Comprehensive genetic 
assessment of individual patients can rarely reveal monogenic cause in EOPD, although 
it may identify the involvement of multiple PD-associated genes in the background of the 
Frontiers in Genetics | www.frontiersin.org October 2019 | Volume 10 | Article 1061
ORIGInal RESEaRCH
doi: 10.3389/fgene.2019.01061
published: 31 October 2019
Genetic Testing of PD in HungaryIllés et al.
2
InTRODUCTIOn
Parkinsonian disorders are a group of progressive neurodegenerative 
movement disorders, in which pathogenesis both genetic and 
environmental factors play a role. Parkinson's disease is the most 
common among them which responsible for approximately 
80% of patients with Parkinsonism. The differential diagnosis of 
Parkinsonism from common idiopathic Parkinson's disease generally 
stands challenges for clinicians, because of heterogeneous phenotypes 
(motor and nonmotor symptoms), related comorbidities, and the 
absence of specific biomarkers (Klein and Schlossmacher, 2006). 
Consequently, in this study, the term Parkinsonian disorders (PDs) 
is used for expressing the different forms of Parkinsonism, which 
include both Parkinson's disease and Parkinson-plus syndromes. 
Until now, several genes were linked to different PD phenotypes, 
which may provide a new possible tool for clinicians to distinguish 
the specific patterns of symptoms or disease course. Moreover, it is 
important to emphasise that, even the similar involvement of these 
disease-genes, the clinical phenotype can be variable, although 
it differs considerably from that of idiopathic PD (Klein, 2005). 
Furthermore, other movement disorders can sometimes mimic 
PD phenotype, which also could make more difficult to set up the 
proper diagnosis without an effective aid by  biomarkers.
Studies with familial and sporadic cases identified large 
number of genetic factors, which are usually not ready to be 
considered for everyday clinical practice. Based on previous 
studies, the rare, highly penetrant pathogenic mutations result 
in monogenic familial forms, although sporadic forms are 
commonly caused by interactions of environmental and genetic 
risk factors (Karimi-Moghadam et al., 2018). Over the past 
few years, the high-throughput next-generation sequencing 
(NGS) technology pave the way to identify the involvement of 
several candidate genes in the development of PD (Shulskaya 
et al., 2018). Dysfunctional protein products resulting from 
rare mutations with functional consequence in these genes are 
generally involved in the mitochondrial and protein quality 
control processes, synaptic transmission, and vesicular recycling 
pathways related to the homeostasis of neurons. Although, more 
and more knowledge is gathered in the field of the underlying 
pathogenesis of PD, and extensive testing of candidate genes is 
in progress, the genetic background still remains unidentified in 
40% of all PD-affected cases (Karimi-Moghadam et al., 2018).
Until now, the nature of inheritance was precisely defined in 
several early-onset PD (EOPD) forms: autosomal dominantly 
inherited PD (AD-PD) is associated with the mutations of LRRK2, 
SNCA, VPS35, ATXN2, and GCH1 genes, autosomal recessive 
form of PD (AR-PD) with mutations of PRKN, PINK1, PARK7, 
ATP13A2, PLA2G6, FBXO7, DNAJC6, SPG11, SYNJ1, and VPS13C 
genes (Spatola and Wider, 2014; Lill, 2016; Lunati et al., 2018). 
Regarding the implication of candidate genes in pathogenesis of PD, 
the available evidences are often not fully convincing. In fact, further 
functional studies are needed to clarify their direct role (such as in 
the case of DNAJC13, TMEM230, UCHL1, RIC3, HTRA2, GIGYF2, 
CHCHD2, EIF4G1, PTRHD1, PODXL, ABCA7, and DCTN1) 
(Araki et al., 2014; Nuytemans et al., 2016; Cardona and Perez-Tur, 
2017; Puschmann, 2017; Lunati et al., 2018).
Monogenic forms of PD are detected relatively rarely, even in 
cases where early-onset and/or familial accumulation suggests a 
strong heritability. In the recent years, the better availability of 
NGS has made it possible for new candidate genes to be identified 
in the background of PD. Analysis of genomic data has revealed 
that rare variants in genes that are linked to PD could provide 
new biological insight into the complex genetic aetiology of the 
disease. Genetic testing may play an increasing role, both in the 
counselling of individual patients and their families with respect 
to the expected disease course and recurrence risks, and in the 
stratification of patient groups in clinical trials (Gasser, 2015).
The aim of this study was to analyse the genetic background 
of EOPD in a Hungarian cohort of patients and to evaluate the 
clinical utility of different genetic investigations. To maximise 
the possibility to find potential causative mutations early-onset 
(25–50 age of onset) and/or positive familiar history were the 
most important selection criteria. Our cohort was analysed by 
covering the most frequent PD-associated genes with Sanger 
sequencing and MLPA analysis. Moreover, we also examined the 
possible involvement of other genes which may relate with PD 
by performing NGS experiments. To date, it has been the first 
comprehensive genetic study on Hungarian patients with PD that 
exploits the opportunities provided by the NGS method.
MaTERIalS anD METHODS
Studied Cohort
Our study involved 142 Hungarian patients, who were diagnosed 
with early-onset (age of onset: 25–50) Parkinsonism based 
disease and may facilitate the better understanding of clinically distinct phenocopies. 
Due to the genetic complexity of the disease, genetic counselling and management is 
getting more challenging. Clinical geneticist should be prepared for counselling of patients 
with coexisting disease-causing mutations and susceptibility factors. At the same time, 
genomic-based stratification has increasing importance in future clinical trials.
Keywords: Parkinson’s disease, next-generation sequencing, genetic risk, monogenic forms, risk factors, early-onset, 
Parkinsonism, Parkinsonian disorders
Abbreviations: ACMG, American College of Medical Genetics; AOO, age of 
onset; D, damaging; DNAJC13, DnaJ heat shock protein family (Hsp40) member 
C13; EIF4G1, eukaryotic translation initiation factor 4 gamma 1; F, familiar 
aggregation; f, female; het, heterozygous; LP, likely pathogenic; LRRK2, leucine 
rich repeat kinase 2; m, male; MAF, minor allele frequency; P, pathogenic; RF, risk 
factor; US, uncertain significance. *Firstly reported in this study.
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on Movement Disorder Society (MDS) criteria (bradykinesia 
in combination with either resting tremor, rigidity, or both) 
(Postuma et al., 2015). Every case was examined by a board-
certified neurologist. Our cohort included 64 females (16 familial 
and 48 sporadic) and 78 males (17 familial and 61 sporadic), the 
mean age of onset in the whole cohort was 40.1 ± 6.92 (Table 1). 
In our cohort, a case was labelled as familial if PD was reported 
among first- or second-degree relatives. In 23 out of 33 familial 
cases, first-degree relatives were affected. All patients were 
born in Hungary and descended from Hungarian ancestors. 
Nonrelated healthy subjects (n = 55, mean AOO = 59.7 ± 17.80) 
and patients without any neurodegenerative symptoms (n = 82, 
mean AOO = 45.1 ± 15.47), who had available whole exome data, 
were screened as controls. In addition, we excluded secondary 
Parkinsonism caused by environmental factors.
Patients and controls were collected from NEPSYBANK 
of the Institute of Genomic Medicine and Rare Disorders at 
Semmelweis University (Molnar and Bencsik, 2006). Written 
informed consent in accordance with the Declaration of Helsinki 
was signed by patients and control subjects before blood 
collection and molecular genetic analysis were made. The study 
was approved by the Hungarian Scientific and Research Ethical 
Committee. Molecular genetic analysis was accomplished for 
diagnostic purposes in all investigated patients.
Molecular Genetic analysis
DNA was extracted from blood using the QIAamp DNA blood 
kit, according to the manufacturer's protocol (QIAgen, Hilden, 
Germany). The whole coding region and exon/intron boundaries 
of PRKN and PINK1 and 14 exons of LRRK2 gene (Nuytemans 
et al., 2010; Cruts et al., 2012), which contained all of the 
previously reported pathogenic substitutions, were analysed 
with Sanger sequencing using ABI Prism 3500 DNA Sequencer 
(Applied Biosystems, Foster City, USA). The genetic sequence 
was compared with the human reference genome (PRKN: 
ENST00000366898.5, NM_004562, PINK1: ENST00000321556.4, 
NM_032409, LRRK2: ENST00000298910.11, NM_198578) 
using NCBI's Blast® application. Exon dosage was pre-typed 
by using multiplex ligation-dependent probe amplification 
(MLPA, SALSA MLPA Kit P051-D1 Parkinson; MRC Holland, 
Amsterdam, Netherlands) according to the protocol. Moreover, 
the most frequent LRRK2 G2019S substitutions were screened by 
the same method.
Altogether, 127 genes (Supplementary Table 1), which were 
previously reported in connection with neurodegenerative 
diseases, were investigated by NGS. During the selection process 
of these genes, we focused on which were previously related to 
PD pathogenesis, with high confidence, or potentially cause 
overlap neurodegenerative diseases.
DNA samples of 54 probands were analysed by whole 
exome sequencing (WES, n = 14) and targeted NGS (n = 40). 
Genomic DNA library preparation was performed using Agilent 
SureSelectQXT Human All Exon v5 reagents and SureSelectQXT 
Target Enrichment for Illumina Multiplexed Sequencing (Agilent 
Technologies, Santa Clara, CA, USA) according to the protocol. 
Library preparation was followed by NGS using Illumina HiSeq 
PE Cluster Kit v4 for cluster generation on cBot, HiSeq SBS Kit 
v4 for sequencing on HiSeq2500 system, and MiSeq Reagent Kit 
v2 (300-cycles) for sequencing on MiSeq (Illumina, San Diego, 
CA, USA).
Bioinformatics analysis
Variant calling from the NGS data was performed by GATK 
HaplotypeCaller (version 3.3-0) following the GATK Best Practices 
Guidelines (Van der Auwera et al., 2013). Variant Call Format (VCF) 
files were annotated with the SnpEff software (Cingolani et al., 2012) 
and ClinVar database (Landrum et al., 2016). Variant filtration of 
exome sequencing data was carried out with VariantAnalyzer 
software developed by the Budapest University of Technology 
and Economics. The nature of novel alterations was established 
according to the American College of Medical Genetics and 
Genomics (ACMG) guideline (Kearney et al., 2011; Richards et al., 
2015). The minor allele frequencies (MAFs) of the variants were 
taken into consideration, predominantly rare variants defined as 
their MAF did not exceed 1%. The MAF was assessed by the data 
of 1,000 Genomes Project (1KG), the Exome sequencing project 
(ESP), Exome Aggregation Consortium Database, and Genome 
Aggregation Database (gnomAD v2.1) using non-neuro (non-
Finnish) population as a reference.
During the analysis, the next step was the selection of known 
disease associated variants, then nonsynonymous variants with 
deleterious prediction scores on the protein function were 
selected. Nonsynonymous alterations were classified based on 
the dbNSFP database (Liu et al., 2013)
Loss of function (nonsense, stop loss/stop gain, frameshift, 
canonical splice) variants and missense variants, which were 
predicted to be deleterious by multiple lines of computational 
evidence, were reserved for further analysis. The MAFs of the 
variants were taken into consideration, predominantly rare variants 
defined as their MAF did not exceed 1%. The MAF was assessed 
by the data of 1KG, the ESP, Exome Aggregation Consortium 
Database, and gnomAD using ALL population as a reference and 
neither population could have higher MAF than 1%. The variants 
which met these criteria and were also not present in the control 
group were considered as damaging and were validated by Sanger 
sequencing. Where family members were available, segregation 
analysis was carried out in the proband's family.
Statistical analysis
Odds ratios (ORs) and 95% Confidence Intervals (CI) were 
calculated to estimate risks using Medcalc software (https://www.
medcalc.org/calc/odds_ratio.php). Quantitative variables were 
described using mean value ± standard deviation (SD).
TaBlE 1 | Hungarian patients with early-onset Parkinsonism.
number of sporadic  
cases (mean aOO ± SD)
number of familial 
cases (mean aOO ± SD)
Male 61 (41.1 ± 6.6) 17 (37.2 ± 6.93)
Female 48 (40.9 ± 6.62) 16 (38.1 ± 7.92)
AOO, age of onset; SD, standard deviation.
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We analysed the effect of rare variant burden on the age at 
onset of the disease. Namely, the age of onset of patients with zero 
(87 patient), one (46 patients), two filtered variants (8 patients) 
were compared with ANOVA test. As three co-occurring variants 
were only present in one patient, that patient was excluded from 
the statistical analysis.
To examine the possibility of oligogenic effect, we performed 
the following analysis. We calculated variant burden in individuals, 
who underwent NGS (either targeted panel sequencing or WES), 
where the same set of genes were assessed, which were covered also 
by the PD-NGS panel (Supplementary Table 1). The following 
groups were created for the analysis: (1) Control group (in total, 
124 individual): this consisted individuals without any disease 
(21 individual), patient with non-neurological diseases (45 
patient), and patients with mitochondrial disorder (58 patient). 
(2) Non-PD neurodegenerative group (in total, 106 patients). 
These patients were diagnosed with a neurodegenerative disease, 
without symptoms of PD (such as hereditary spastic paraparesis, 
ataxia, amyotrophic lateral sclerosis, and dementia). (3) Patients 
with PD, who underwent NGS testing (54 patients). We defined 
variant burden as the total number of filtered variants in every 
gene represented on the NGS targeted panel (in total, 127 genes). 
Heterozygous variants were counted as 1 hit, homozygous 
variants as 2 hits. Summing all the hits in all the 127 genes resulted 
in the final variant burden. We tested the null hypothesis that the 
distribution of the individual variant burdens in the three groups 
(control, PD, non-PD neurodegenerative) came from the same 
sample with Kruskal-Wallis test. We calculated variant burden 
with an increasingly stringent filter criteria and tested statistical 
significance on every level for the three above defined group. 
The following filter criteria were created. (A) maximum MAF in 
any population is <1% AND effect of mutation is either loss of 
function (stop gain, stop loss, frameshift, canonical splice site) 
or missense. (B) The same filter as (A), but only those missense 
variants were counted, where multiple lines of computational 
evidence suggested damaging effect. (C) The same filter as (A), 
but only those variants were counted, which were present in a 
core PD gene list. These genes are the union of genes listed in the 
OMIM database or GeneReviews as associated with Mendelian 
forms of Parkinsonism, namely, GBA, LRRK2, PARK7, PINK1, 
PRKN, SNCA, VPS13C, VPS35, ATP13A2, DNAJC6, FBXO7, 
SLC6A3, SYNJ1, DNAJC13, CHCHD2, PLA2G6, EIF4G1. (D) The 
same filter as (C), but only those missense variants were counted, 
where multiple lines of computational evidence suggested 
damaging effect.
RESUlTS
In our study, 142 unrelated probands with Parkinsonism 
were analysed, from which, 33 cases familial aggregation of 
neurodegenerative disorders were reported. The identified 
variants were classified into four groups: (1) rare damaging 
mutations in PD-associated genes, potentially compatible with 
a monogenic PDs; (2) previously reported genetic risk variants 
of PD; (3) multiple-hit mechanism impacting the risk of PD; (4) 
single heterozygous mutations in AR-PD-associated genes.
Rare Damaging Mutations in 
PD-associated Genes, Potentially 
Compatible With a Monogenic PD
In the PRKN gene, exon 7 duplication were detected in four 
sporadic patients. In case of one sporadic patient, SNCA gene 
duplication was identified. All of the detected CNVs were 
classified as pathogenic based on ACMG classification guideline. 
A previously reported, LRRK2 L1795F pathogenic mutation 
(Nichols et al., 2007) were detected in a single case (P15). In 
addition, novel damaging mutations were identified both in 
LRRK2 (Y1649S) and EIF4G1 (M1357T) genes in the P123 and 
P2 patients, respectively. The L2170W mutation in DNAJC13 
gene was classified as a variant with unknown significance, 
although Gustavsson et al. in 2015 suggested that this variant 
increase the genetic risk of PD (Gustavsson et al., 2015). Neither 
of these variants were detected in our control group and the two 
LRRK2 (L1975F and Y1649S) mutations were not presented in 
gnomAD database. All the identified damaging SNVs were found 
in patients with familial aggregation. Clinical characteristics of 
the patients are reported in Table 2. Patients with PRKN exon 
7 duplication, who are not involved in this Table, did not have 
atypical neurological symptoms. Two patients had equivalent, 
and two patients had akinetic-rigid type of PD. Mean age at 
onset in this group of patients was 42.25 ± 5.0 years. The P140 
male patient has akinetic-rigid type of PD without any atypical 
symptoms (AOO = 44).
Previously Reported Genetic Risk  
Variants of PD
In our cohort, 25 sporadic cases were identified with previously 
published genetic risk variants in PD genes (22.94% of sporadic 
cases) (Table 3). This rate is approximately two times higher in 
familiar cases (45.46%), where 15 patients carried risk variants. 
In this Hungarian population, heterozygous GBA mutations, 
such as H294Q, E365K, T408M, N409S, and L483P variants, 
were identified in 10 patients (7.04%) and four controls (3.42%). 
The detected H294Q, L483P, and N409S GBA variants were 
published as pathogenic in biallelic form in GD. The T408M 
variant based on ClinVar is considered as benign, the E365K as 
VUS in GD; however, previous studies identified both of them 
as genetic risk variants for PD (Benitez et al., 2016; Barkhuizen 
et al., 2017). Moreover, one patient (P18) carried two previously 
published genetic PD risk variants in GBA gene. Among the GBA 
carriers, some patients had distinctive clinical features, such as 
supranuclear vertical gaze palsy (P25), nonmedication associated 
hallucinations (P19), depression and anxiety (P13, P18), and 
early cognitive dysfunction in two patients (P13, P24).
Segregation studies were successful in three cases: P10 had 
L483P/c.1448T>C mutation, his father, fraternal grandmother, 
and her sister carried the same rare variant in the GBA gene. The 
sister has late-onset PD with severe cognitive dysfunction. Other 
family members did not have any PD signs or symptoms. P13 
harbours the H294Q/c.882T>G mutation. His grandfather and 
the brother of his grandfather had late-onset PD. We were able to 
analyse his father who has no signs of PD but carries the mutation. 
P25 patient carries the heterozygous T408M/c.1223C>T mutation. 
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TaBlE 2 | Patients with rare substitutions in AD-PD-associated genes.
Patient 
ID
Form aOO Sex Symptoms Gene Variant ID Zygosity Clinical 
significance
aCMG 
classification
MaF Patients Controls Reference
P15 F 25 f tremor, slower and altered 
handwriting, depression, anxiety
LRRK2 L1795F
c.5385G>T
rs111910483
het P LP <0.01 1/142 0/117 (Nichols et al., 
2007)
P123 F 34 m hypomimia, tremor, rigidity, 
bradykinesia, postural instability, 
freezing, depression
LRRK2 Y1649S
c.4946A>C
–
het D LP – 1/142 0/117 *
P46 F 30 m tremor, rigidity, bradykinesia, 
decreased synkinesis of arms, 
depression
DNAJC13 L2170W
c.6509T>G
rs140537885
het D/RF US <0.01 2/54 0/117 (Gustavsson 
et al., 2015)
P2 F 33 f tremor, decreased synkinesis of 
arms
EIF4G1 M1356T
c.4067T>C
rs144059151
het D US <0.01 1/54 0/117 *
For minor allele frequency (MAF), we used the gnomAD database non-neuro group (v2.1) of European population (non-Finnish). F, familiar aggregatio; f, female; m, male; LRRK2, leucine rich repeat kinase 2; DNAJC13, DnaJ heat 
shock protein family (Hsp40) member C13; EIF4G1, eukaryotic translation initiation factor 4 gamma 1; het, heterozygous; P, pathogenic; D, damaging; RF, risk factor; ACMG, American College of Medical Genetics; LP, likely pathogenic; 
US, uncertain significance; AOO, age of onset; MAF, minor allele frequency. *Firstly reported in this study.
TaBlE 3 | Previously described genetic risk factors associated with PD. 
Patient ID Gene Variant ID Zygosity MaF Patients Control Sporadic Familial Mean aOO OR p Reference
P10 GBA L483P
c.1448T>C
rs421016
het <0.01 1/54 0/137 – 1 27 7.7 0.21 (Benitez et al., 2016)
P13 GBA H294Q
c.882T>G
rs367968666
het <0.01 1/54 0/137 – 1 30 7.7 0.21 (Benitez et al., 20
16)
P16, P17 GBA E365K
c.1093G>A
rs2230288
het 0.01 2/54 1/137 2 – 47 5.2 0.18 (Barkhuizen et al., 2017; 
Benitez et al., 2016)
P8, P18, P23, P24, P25 GBA T408M
c.1223C>T
rs75548401
het <0.01 5/54 2/137 3 2 33.6 6.9 0.02 (Barkhuizen et al., 2017; 
Benitez et al., 2016)
P18, P19 GBA N409S
c.1226A>G
rs76763715
het <0.01 2/54 1/137 2 – 36 5.2 0.18 (Barkhuizen et al., 2017; 
Benitez et al., 2016)
P26, P31, P43, P104 LRRK2 M1646T
c.4937T>C
rs35303786
het 0.02 4/142 0/137 2 2 43.8 8.9 0.15 (Paisán-Ruiz et al., 2013)
P1, P6-P7, P14, P21-P22, 
P40-P41, P51, P57-P58, 
P61, P73-P76, P88, P110, 
P117, P121, P124
LRRK2 S1647T
c.4939T>A
rs11564148
hom 0.31 21/142 14/137 13 8 41.7 1.5 0.25 (Zheng et al., 2011)
P11, P56, P62, P93 PINK1 A340Tc.1018G > 
Ars3738136
het 0.05 4/142 12/137 3 1 39 0.3 0.04 (Wang et al., 2006)
P1, P28 PINK1 G411Sc.1231G > 
Ars45478900
het <0.01 2/142 1/137 1 1 36.5 1.9 0.59 (Puschmann et al., 2017)
For minor allele frequency (MAF), we used the gnomAD database non-neuro group (v2.1) of European population (non-Finnish). AOO, age of onset; het, heterozygous; hom, homozygous; GBA, glucosylceramidase beta; LRRK2, leucine 
rich repeat kinase 2; MAF, minor allele frequency; OR, odds ratio; PINK1, PTEN induced kinase 1; p, probability value.
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His brother with similar symptoms also carries this heterozygous 
substitution. The healthy mother has no mutation in the GBA 
gene, and the father died at the age of 41. The father's sibling also 
suffered from PD, so we supposed that the brothers inherited the 
c.1223C>T substitution from their father.
In the LRRK2 gene, the heterozygous M1646T mutation was 
found in four patients compared to zero in control group. In 21 
patients (14.8%), LRRK2 S1647T substitution was detected in 
homozygous form, which were previously suggested to contribute 
PD risk (Zheng et al., 2011). However, it was also detected in our 
control group in homozygous form in 14 subjects (10.22%). The 
PINK1 A340T polymorphism was identified in four cases among 
patients and in 12 control subjects. The G411S substitution was 
also detected in two cases and one control in our cohort.
Among all the detected, previously published genetic risk 
variants, all of it are associated with an OR > 1 in our cohort; 
however, we could only confirm two risk variants (GBA T408M 
and PINK1 A340T), to be significantly more frequent in cases, 
compared to controls.
Multiple-Hit Mechanism Impacting the 
Risk of PD
It is hard to interpret multiple-hit mechanism on an individual level. 
However, we have observed in nine cases that heterozygous damaging 
mutations in AR-PD-associated genes coexisted with either a known 
risk or a rare variant in another PD-associated gene (Table 4). The 
coexistence of the LRRK2 risk variant and an additional heterozygous 
missense mutation of PRKN, PINK1, or SYNJ1 might be compatible 
to an oligogenic model. In three cases, LRRK2 S1647T homozygous 
risk variant was present simultaneously with heterozygous PRKN 
(C446S), PINK1 (R501Q), or SYNJ1 (Q1163E) substitutions, 
respectively. In the case of P7 patient, we assume that the previously 
unpublished C446S mutation in PRKN gene is probably pathogenic 
based on the in silico prediction scores and segregation analysis. P7's 
father, who has later onset PD, was carrying heterozygous PRKN 
C446S and LRRK2 S1647T mutations and P7's unaffected mother 
was carrying heterozygous LRRK2 S1647T substitution. The PINK1 
R501Q alteration was consistently predicted as damaging. Finally, 
a rare damaging SYNJ1 Q1163E substitution was found in a male 
patient with typical features of PD. In two other cases, the LRRK2 
M1646T alteration was identified with other PD-related mutations, 
such as PRKN heterozygous R234Q substitution with damaging 
prediction scores in P26 or a novel DNAJC13 heterozygous D1301V 
damaging substitution in P43 (Table 4). We hypothesised that, if a 
genetic risk factor is concomitantly present with a rare heterozygous 
damaging mutation, it results in earlier onset of symptoms, 
compared to cases with a single PD risk variant.
In order to test the hypothesis of oligogenic inheritance pattern, 
we performed two analyses. Firstly, we tested with ANOVA, whether 
patients with more than one filtered genetic variant (presented in 
Table 4, in total nine patients) have different distribution of age at 
onset from those, who harbour only one filtered variants (presented 
in Tables 2, 3, and 5, in total 46 patients). We could only observed a 
trend to have lower mean and median age at onset with increasing 
number of filtered co-occurring variants; however, this did not reach 
the level of statistical significance (Figure 1A).
Secondly, we tested the hypothesis with the Kruskal-Wallis 
statistics, that in patients with Parkinsonism, there is a greater 
variant burden in PD-associated genes compared to non-PD 
neurodegenerative patients, and control individuals, as described 
in the Statistics section. Surprisingly, with the most relaxed filter 
criteria (MAF < 1%, AND loss of function or missense variants), 
we observed that there is a significantly greater number of 
variants in the control group (Figure 1B) compared to the 
PD-patient group. However, when we performed the analysis 
with a stringent filter criterion (MAF < 1% AND loss of function 
or damaging missense variant in core PD-genes), we observed 
that this difference diminished, and even seemed to turn around. 
However, this did not reach the level of statistical significance.
Single Heterozygous Mutations in aR-PD 
associated Genes
In one sporadic case, pathogenic R275W heterozygous mutation 
was identified in PRKN gene, and in three sporadic cases, possible 
damaging substitution were identified in autosomal recessively 
inherited genes, such as DNAJC6 (F414Y), CP (I898M), and 
PLA2G6 (R396W) (Table 5). Notably, AOO is comparably high 
as it was seen in case where previously described genetic risk 
factors were solely presented (Table 3).
DISCUSSIOn
This is the first genetic epidemiology study targeting disease 
genes of early-onset PD in Hungary, in which several genetic 
alterations were identified in PD-associated genes. Since the 
monogenic forms cause only a minority of EOPD, there is a 
need to identify the most cost-effective diagnostic workup for 
these patients. Genetic analysis of Hungarian EOPD patients 
revealed mutations affecting several genes with varying degree 
of association, such as DNAJC6, DNAJC13, EIF4G1, GBA, 
LRRK2, PRKN, PINK1, PLA2G6, SNCA, and SYNJ1. Studying the 
functions of their protein products further elucidate the potential 
role and interplay in the pathomechanism of neurodegeneration, 
like mitochondrial dysfunctions and impaired autophagy-based 
protein or organelle degradation pathways, which indeed can 
lead to development of PD (Ryan et al., 2015).
The possibility to identify more than one rare variant in a PD 
patient is not uncommon based on our and others observations 
(Lubbe et al., 2016; Keogh et al., 2018) in the era of NGS. In 
our cohort, nine cases were presented with potential oligogenic 
interaction in the background of their symptoms, from 
which seven cases had a positive family history (Table 4). The 
coexistence of LRRK2 M1646T or S1647T risk variants (Zheng 
et al., 2011; Paisán-Ruiz et al., 2013) with further heterozygous 
rare damaging missense mutations of PRKN, PINK1, or SYNJ1 
might suggest an oligogenic inheritance. The LRRK2 risk variants 
with mutations in AR-PD-associated genes raised the possibility 
that maybe these explain the earlier age of onset in these patients. 
Further analysing the modifying effects of these risk variants, 
especially if they are associated with recessive heterozygous rare 
damaging mutation, could potentially clarify the PD prognosis. 
In our cases, oligogenicity was supposed if a patient had more 
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TaBlE 4 | Double-hit mechanism impacting the risk of PD: Rare damaging variants and previously described genetic risk factors affecting more than one PD associated genes. 
Patient 
ID
Form aOO Sex Symptoms Gene Variant ID Zygosity Clinical 
significance
aCMG 
classification
MaF Patients Controls Reference
P7 F 43 m hyposmia, dysarthria, tremor, 
bradykinesia, postural instability, 
dysdiadochokinesis, MCI
PRKN C446S
c.1336T>A
–
het D P – 1/142 0/137 *
LRRK2 S1647T+
c.4939T>A
rs11564148
hom RF – 0.31 21/142 14/137 (Zheng et al., 2011)
P26 F 40 f tremor, postural instability, 
disturbed vision, MCI
PRKN R234Q
c.701G>A
rs144032774
het D US <0.01 1/142 0/137 *
LRRK2 M1646T+
c.4937T>C
rs35303786
het RF – 0.02 4/142 0/137 (Paisán-Ruiz et al., 
2013)
P21 F 39 f rigidity, bradykinesia, postural 
instability
PINK1 R501Q
c.1502G>A
rs61744200
het D US <0.01 1/142 0/137 (Marongiu et al., 
2008)
LRRK2 S1647T+
c.4939T>A
rs11564148
hom RF – 0.31 21/142 14/137 (Zheng et al., 2011)
P22 F 37 m dysarthria, hypophonia, 
bradykinesia, tremor, RBD, 
medication associated 
fluctuations with OFF 
dystonia, panic attacks, MCI
SYNJ1 Q1163E
c.3487C>G
rs768503724
het D US <0.01 1/54 0/137 *
LRRK2 S1647T+
c.4939T>A
rs11564148
hom RF – 0.31 21/142 14/137 (Zheng et al., 2011)
P43 S 38 f tremor, rigidity, decreased 
synkinesis of arms
DNAJC13 D1301V
c.3902A>T
rs748182915
het D/RF LP <0.01 1/54 0/137 *
LRRK2 M1646T
c.4937T>C
rs35303786
het RF – 0.02 4/142 0/137 (Paisán-Ruiz et al., 
2013)
P18 S 31 m tremor, bradykinesia, rigidity, 
frequent freezing, depression, 
anxiety
GBA T408M+
c.1223C>T
rs75548401
het RF – <0.01 5/54 2/137 (Barkhuizen et al., 
2017; Benitez 
et al., 2016)
GBA N409S+
c.1226A>G
rs76763715
het RF – <0.01 2/54 1/137 (Barkhuizen et al., 
2017; Benitez et al., 
2016)
P20 F 39 m tremor, rigidity, Parkinsonian 
gait, anxiety, MCI
PLA2G6 V630G
c.1889T>G
–
het D P – 1/54 0/137 *
DNAJC13 R2115Q
c.6344G>A
rs770715465
het D/RF US <0.01 1/54 0/137 (Vilariño-Güell 
et al., 2014)
P4 F 39 f dysarthria, tremor, postural 
instability, bradykinesia, rigidity, 
orthostatic hypotension, low 
iron level, MCI
C19orf12 L61*
c.182T>G
–
het P P – 1/54 0/137 *
(Continued)
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than one variant (either rare damaging or common risk variant) 
in different PD-associated genes. Although these observations are 
interesting, it is hard to interpret them on an individual level. In 
order to support statistically the possibility of an oligogenic effect, 
we tested two hypotheses. We asked, whether those patients, 
who simultaneously carry more than one PD-associated variant, 
have earlier age at onset. We could observe a trend, however, this 
did not reach statistical significance (Figure 1A). The second 
question we asked was, whether patients, who are diagnosed with 
PD, more commonly carry rare variants in PD-associated genes 
compared to other patients with neurodegenerative diseases or 
controls. Surprisingly, we have observed that more rare variants 
were detected if a permissive filter criterion was defined, but this 
difference diminished with more stringent filter criteria. When we 
applied a rigorous filter criterion, it even seemed that this trend 
turns around; however, this did not reach statistical significance 
(Figure 1B). Furthermore, we observed a potential trend in 
our cohort, that those patients with co-occurring variants had 
a greater chance for being labelled as familial. In summary, we 
can only raise the suspicion of an oligogenic effect, but probably 
much larger cohort are needed to prove this unequivocally.
It has to be emphasised, that limitation of statistical 
comparison, which is not only the small number of cases (as 
only 54 of our patients were analysed by NGS; thus, it is possible 
that they may harbour additional variants in genes that were not 
covered). But, the different penetrance of the coexisting genetic 
risk factors (e.g., the low penetrance LRRK2 S1647T versus a 
pathogenic GBA H294Q mutation), and these tests need to be 
repeated in larger samples.
The MLPA analysis identified five cases with pathogenic 
mutation from the 142 EOPD patients (3.5%), while Sanger 
sequencing revealed potential damaging mutation of LRRK2 
in two cases and risk variants in PINK1 and LRRK2 genes in 
28 cases (19.7%). Co-occurring variants were detected in three 
patients (2.1%). A heterozygous PRKN mutation was detected in 
a single case (0.7%). The NGS of 54 patients revealed mutations 
affecting several other PD-associated genes (CP, C19ORF12, 
DNAJC6, DNAJC13, EIF4G1, GBA, PLA2G6, SYNJ1). Two 
patients carried heterozygous variants in AD-PD genes (3.7%; 
LRRK2, DNAJC13, EIF4G1), while 10 patients carried GBA 
mutations (18.5%). Six patients were identified with potential 
oligogenic interactions with the coexistence of genetic risk factor 
or heterozygous rare variants in PD-associated genes (11.1%). 
Three patients carried a single heterozygous mutation in an 
AR-PD gene (5.6%). Altogether, we conclude that whole exome 
sequencing potentially increased the number of relevant findings.
Among the 109 sporadic cases, five patients have CNVs in 
PRKN or SNCA genes. Deletions and duplications/triplications 
of one exon or exon groups account for a significant proportion 
of mutations in the PRKN gene (Shulskaya et al., 2017). In 
a Dutch cohort, the exon 7 duplication was suggested to be 
a founder mutation based on haplotype analysis and shared 
similar breakpoints (Elfferich et al., 2011). The importance of 
CNVs in PRKN gene was supported by our results as well, since 
23.5% of our solved cases (consistent either to oligogenic or AD 
inheritance) harboured PRKN exon rearrangement, which were 
presumed to be more deleterious, because they caused altered 
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FIGURE 1 | Results of the analysis of oligogenic effects. Panel (a) shows the result of analysis coexisting variants (multiple-hits) on the age at onset. The box plots 
show the distribution of the age at the onset of symptoms if zero, one, two, or three simultaneous variants were present. Solid lines show medians and dashed 
lines the means. Differences between groups were not significant with ANOVA test. Panel (B) shows variant burden in the groups defined at the Methods section. 
Deg = patients with neurodegenerative diseases, without signs of Parkinsonism. Park = patients with Parkinsonism. We present the results with the least and most 
stringent filter criteria set. On the upper part of panel (B) (less stringent filters), we can see that more variants were present in the control group, which actually 
reached the level of statistical significance. On the lower part of panel (B) (most stringent applied filters), we can see that this difference diminished and even 
seemed to turn-around; however, in this case, the difference was not significant.
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PRKN protein function by reorganising the protein structure 
(Pankratz et al., 2011). These findings suggest that examination of 
CNVs in most frequently affected genes may be cost-effective in 
routine clinical practice for diagnosing PD and could be offered 
as a first step if the genetic workup is considered.
Moreover, PD susceptibility factors in GBA, LRRK2, and 
PINK1 genes were relatively common in our cohort. These 
variants can be important from clinical point of view since some 
of them may serve as an important factor for stratification for 
clinical trials, such as GBA, others may contribute as modifiers 
to the complex aetiology of the disease. Most of the potential 
genetic risk factors of PD have been detected in genes which were 
previously associated with Mendelian inherited PD. According 
to the hypothesis of Sparato et al. (2017), genes harbouring both 
causal mutations for Mendelian disorders and risk variants for 
complex diseases may have high functional relevance in the 
pathogenesis (Spataro et al., 2017). In our cohort, we observed 
a similar frequency of genetic risk variants as reported in 
the literature (Karimi-Moghadam et al., 2018). In the future, 
potential therapeutic intervention could be planned based on 
some genetic risk variants, similarly to glucosylceramide synthase 
(GCS) inhibition of GBA associated PD (Sardi et al., 2017).
In our study, we identified four rare damaging heterozygous 
mutations in AR genes (Table 5), which suggested a potential 
role in the PD pathogenesis (Makovac et al., 2016; Ferese 
et al., 2018). Other studies suggested that approximately 
5%–10% of sporadic EOPD patients carried heterozygous 
mutation in AR-PD-associated genes (Periquet et al., 2003; 
Clark et al., 2006). In our cohort, similar distribution 
(7.21%) was detected. Furthermore, it remains a question 
of debate how heterozygous alteration in recessive genes 
could contribute to the development of EOPD. Some results 
indicated that heterozygous mutations may simply result in 
subclinical cellular dysfunction or predispose PD (West et al., 
2002; Periquet et al., 2003; Hedrich et al., 2004). Additionally, 
single heterozygous mutations in PRKN and PINK1 genes are 
considered minor genetic risk factors for developing PD and 
single heterozygous substitutions in PRKN gene have been 
described in sporadic, late-onset PD (Spatola and Wider, 2014). 
Furthermore, the previously described mutations can cause 
malfunction in the metabolism of dopamine in the striatum 
and brain network changes, leading to cognitive impairment 
(Hilker et al., 2001; Khan et al., 2002; Benbunan et al., 2004; 
Ricciardi et al., 2014; Makovac et al., 2016). Moreover, other 
authors suggested that heterozygous mutations in PLA2G6 
may also contribute to the susceptibility for developing PD 
(Ferese et al., 2018), as some PLA2G6 heterozygous mutations 
were presented in PD patients (Bower et al., 2011; Lu et al., 
2012). We assume that the I898M damaging mutation in the 
CP gene, which plays an important role in the iron and copper 
metabolism in the brain (Zhao et al., 2018), could intensify the 
risk of developing PD. These four patients in Table 5 with a 
mean AOO (42 ± 5.72 years) is rather like the sporadic patients 
with a single genetic risk variant presented in Table 3 with a 
mean AAO (40 ± 6.94 years) than the sporadic patients with 
potential oligogenic background (presented in Table  4 with 
a mean AOO 34.5 ± 4.95 years). Examining mutations in Ta
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AR-PD-associated genes may be essential to further specify 
the contribution of heterozygous mutations in patients with 
EOPD. Additional studies need to further elucidate whether 
these variants are potential AD-PD-inducing mutations, or 
they act as risk factor with coexisting genetic susceptibility and 
environmental effects. Exploring the function of monoallelic 
alterations in AR-PD may be crucial for possible future use 
of genetic data for improvement of genetic counselling in 
individualised settings.
The genetic testing in PD is complex and it depends on 
whether testing is being requested by someone who has PD 
or someone who has positive family history of PD, without 
symptoms of PD. The complexity is coming from the fact that 
several genes and risk factors are associated with PD. In many 
patients with PD, even if they have a family history for PD, the 
disease-causing abnormal genes cannot be detected. Notably, the 
genetic counselling is specially challenging in those cases where 
(1) several genetic risk factors or (2) a genetic risk factor and a 
heterozygous carrier status of a pathogenic or likely pathogenic 
mutation is coexisting (Figure  2). The co-segregation analysis 
of these coexisting rare variants can facilitate understanding 
the role of these variants. The GBA variants may have particular 
importance, based on the published data, it seems that, even 
in heterozygous status the variant, which has a more severe 
effect to the protein, has greater impact on the disease onset 
and progression (Zhang et al., 2018). The clinicians should 
differentiate in counselling where a healthy person without any 
family history request the counselling asking the risk scores 
of different genetic disorders (among them PD), or a patient 
having PD asking the recurrence risk in the next generation, 
or if the genetic results of the relatives of a PD patients has to 
be interpreted. Nevertheless, the situation is complicated if the 
person has monoallelic deleterious rare variant in AR inherited 
PD. In cases having coexisting monoallelic rare pathogenic 
variant and alteration(s) in genes which could potentially increase 
PD susceptibility or having more than one rare variant in those 
genes the risk of disease development is greater. Furthermore, it 
is important to highlight those further gene-gene interactions 
and environmental factors also influence the manifestation of 
the genetic background. In some cases, potential disease-causing 
mutation in previously PD-associated gene will not ensure the 
occurrence of PD symptoms during the life of the patient due to 
the reduced penetrance. Additionally, it is crucial that the genetic 
counsellor must be familiar with all those distinctive phenotypic 
features which can be associated with the different PD-associated 
genes (e.g., GBA, DNAJC6, SYNJ1) since in some cases with likely 
pathogenic variants or VUS in PD-associated genes, the reverse 
phenotyping is an important task (Figure 2). In our cohort, not 
only GBA PD cases had distinctive clinical features, but a patient 
with heterozygous PLA2G6 variant (P9) had hallucinations, 
proximal weakness in the lower extremity, spasticity, urinary 
incontinence (Table 5). MRI showed severe white matter 
FIGURE 2 | Clinical interpretation of genetic test results and tasks associated with the genetic counselling. The first column represents the most common 
situations emerging after genetic testing in PD. On the top, we included the more easily interpretable findings, and on the bottom, the commonly emerging 
challenges. On every level, many aspects of the genetic findings have to be interpreted by the genetic counsellor, and we only included the major questions 
associated with a level. At the last column, we included important tasks of the genetic counsellors associated with a given level; however, naturally in every level, a 
complex approach is needed.
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lesions. Early cognitive dysfunction was present in a patient 
(P22), who carried heterozygous variants in SYNJ1 and LRRK2 
(Table 4). This patient also had early and severe medication 
associated fluctuations with frequent OFF dystonia. Orthostatic 
hypotension was early and severe in a patient with heterozygous 
C19orf12 variant (P4) (Table 4). In a patient, who carried a 
heterozygous CP variant (P27) had low serum ceruloplasmin 
level. To collect all this type of phenotypic observations are very 
important for further understanding the genotype-phenotype 
correlations in PD.
To identify the genetic background is important not only 
in family planning but there is an increasing need in the era of 
the personalised medicine to stratify the patient based on their 
genetic background. There are clinical trials, which are focusing 
on the treatment of patients with certain genetic alterations, such 
as heterozygous GBA variants. Ideally, to reach personalised 
therapeutic interventions in the future, a systems biology 
approach would be optimal analysing multidimensional clinical 
and genetic/genomic risk and progression profile.
In summary, our study further supports the hypothesis that 
alterations in Mendelian PD-associated genes may act as a 
genetic risk factor for the sporadic form and even a heterozygous 
mutation in AR-PD genes could contribute to the disease 
susceptibility. With better availability of NGS technologies for 
clinical assessment, genetic testing is getting more important tool 
in the clinical practice and research of the EOPD. Application of 
NGS can effectively identify coexisting pathogenic rare variants 
and genetic susceptibility factors which could have significant 
role in understanding the complex pathogenesis of PD. The 
simultaneous analysis of neurodegeneration-associated genes 
could support both the diagnostic workup and the interpretation 
of clinically distinct phenocopies associated with certain 
single or coexisting genetic alterations and the spectrum of 
the neurodegenerative disorders. Due to the complexity of the 
disease and improving availability of NGS technologies, genetic 
counselling is getting more challenging by the increasing number 
of PD-associated rare variants. Thus, the clinical geneticist 
should be prepared for the genetic counselling of patients with 
coexisting disease-causing mutations and susceptibility factors. 
In the near future, coexistence of major disease-causing mutation 
and minor susceptibility factors could be interpreted at the level 
of individual.
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